Chuang Peng - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Chuang Peng

Showing results (101-110 of 103) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 103 results.

The Lancet. Oncology|May 11, 2025

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.

Bioscience Trends|August 13, 2025

Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 editionSulai Liu, Jinqiong Jiang, Qian Jian, et al.

Hepatobiliary Surgery and Nutrition|June 11, 2026

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)Zheng Wang, Huichuan Sun, Jian Zhou, et al.

Pageof 11

Search research articles

Showing results (101-110 of 103) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 103 results.

The Lancet. Oncology|May 11, 2025

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.

Bioscience Trends|August 13, 2025

Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 editionSulai Liu, Jinqiong Jiang, Qian Jian, et al.

Hepatobiliary Surgery and Nutrition|June 11, 2026

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)Zheng Wang, Huichuan Sun, Jian Zhou, et al.

Pageof 11